3 ASX blue chip shares to buy with $10,000

If you have $10,000 available to invest, blue chip ASX shares can be a good place to start looking.

These are businesses with scale, strong market positions, and long-term growth drivers. They may not always be the fastest movers on the market, but the best blue chips have a habit of compounding value over time.

With that in mind, here are three ASX blue chip shares to consider buying with $10,000.

Goodman Group (ASX: GMG)

Goodman Group remains one of the most attractive large-cap shares on the ASX.

The company owns, develops, and manages industrial property around the world. Its assets are used by customers that need well-located logistics facilities, warehouses, and increasingly, data centre infrastructure.

That last point is becoming more important. Goodman is no longer just a play on e-commerce and supply chains. It is also becoming increasingly exposed to the growth in cloud computing, artificial intelligence, and digital infrastructure.

This gives the business several long-term growth drivers. Retailers need faster fulfilment networks, companies need smarter logistics, and technology groups need large-scale sites for data centres.

Goodman’s strength is that it owns the type of scarce land and development capability needed to support these trends.

With demand for logistics and data infrastructure continuing to grow, Goodman remains a blue chip share with a strong long-term outlook.

ResMed Inc (ASX: RMD)

ResMed Inc is another ASX blue chip share that looks well placed for the years ahead.

The company is a global leader in sleep apnoea treatment and respiratory care. Its devices, masks, and software help patients manage breathing-related conditions, with demand supported by ageing populations and rising awareness of sleep health.

Its recent result shows that the company continues to perform positively. In the third quarter, ResMed delivered an 11% increase in revenue to US$1.4 billion, while earnings per share rose 21% after its gross margin expanded by 290 basis points to 62.8%. This was driven by cost improvements and manufacturing efficiencies.

This is not just a volume growth story. The margin improvement shows ResMed is also becoming more profitable as it scales.

The company is also investing in digital health, connected devices, and home healthcare. These areas could become more important as healthcare systems look for ways to treat more patients outside traditional hospital settings.

With strong demand, improving profitability, and a clear role in the future of home healthcare, ResMed remains a high-quality ASX blue chip to consider.

TechnologyOne Ltd (ASX: TNE)

TechnologyOne is another ASX blue chip share to consider buying with the $10,000.

The company provides enterprise software to government departments, universities, councils, and large organisations. These customers rely on its products for critical functions, which helps make revenue more predictable.

TechnologyOne’s shift to software-as-a-service has strengthened the business. Recurring revenue has increased, customer relationships have deepened, and the company has gained better visibility over future earnings.

That consistency is a major part of the appeal. TechnologyOne has built a long track record of earnings growth, supported by disciplined execution and a clear product strategy.

Its opportunity is not limited to Australia. The company has also been expanding in the United Kingdom, giving it another pathway for growth over the long term.

With recurring revenue, mission-critical software, and a proven management team, TechnologyOne is arguably one of the ASX’s strongest blue chip technology shares.

The post 3 ASX blue chip shares to buy with $10,000 appeared first on The Motley Fool Australia.

More reading

• Should you sell in May and stay away?
• Why I’d buy and hold these ASX 200 blue-chip shares for at least 5 years
• 10 excellent ASX shares to buy in May
• Why EQ Resources, Inghams, ResMed, and Skycity shares are tumbling today
• What’s going on with ResMed shares today?

Motley Fool contributor James Mickleboro has positions in Goodman Group, ResMed, and Technology One. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goodman Group, ResMed, and Technology One. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Goodman Group and Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.